Eli Lilly Joins the Trillion Dollar Club as Weight Loss Drugs Prove Pharma’s Golden Ticket

Medicine has a new favorite headline, and it begins with a weight loss needle. Eli LillyLLY

touched $1T in market capitalization on Friday, becoming the 10th company — and the first drugmaker — to reach that milestone. Driving the surge are the GLP-1 drugs Mounjaro and Zepbound, which help patients lose nearly a quarter of their body weight while also reducing heart-attack risk and treating liver disease.

• Lilly’s tirzepatide drugs are on pace to generate over $40B in annual sales by 2026 and could approach $60B by 2030, putting them in line to become the bestselling medicines in history.
• It now leads in new obesity-drug prescriptions, surpassing Novo NordiskNVO
  as its valuation slips toward $200B, and has grown to more than twice the size of Johnson & JohnsonJNJ
  .

The weight of success: Analysts expect Eli Lilly’s GLP-1 sales to top $100B by 2034 — well above the $63B projected across all its products this year. It also has momentum from launching its weight loss pill into a more stable market with better insurance coverage, setting up strong near-term growth even with a patent cliff on the horizon. As it stands, Lilly currently holds the strongest hand in healthcare.